Physician profile
Rajiv Sood
NPI 1235163387
$502,244.08
in general payments reported to CMS, 2019-2025
15 companies · $159K in 2025
The $159K reported for 2025 was more than what 99% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $31K · 2021: $27K · 2022: $19K · 2023: $96K · 2024: $126K · 2025: $159K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $165K · Travel and Lodging: $96K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $49K · Honoraria: $38K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $9,158 · Education: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $164,539.23 |
| Travel and Lodging | $95,580.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $49,470.00 |
| Honoraria | $37,730.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,825.00 |
| Food and Beverage | $9,157.55 |
| Education | $3,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $216,607.65 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Smith+Nephew, INC. | $201,145.28 | 2019-2025 | Oasis, Collagenase Santyl, Acticoat 4" X 4" |
| Avita Medical Americas, LLC | $72,621.69 | 2019-2025 | Recell, Permeaderm, Cohealyx |
| Polynovo North America LLC | $4,219.53 | 2021-2025 | Novosorb Btm |
| Cook Biotech Incorporated | $2,533.23 | 2019 | |
| Integra Lifesciences Corporation | $2,500.00 | 2019 | |
| Vericel Corporation | $2,200.00 | 2019 | |
| Baxter Healthcare | $159.88 | 2021-2024 | Artiss |
| Lumenis, INC | $93.77 | 2021 | |
| Triad Life Sciences INC. | $39.61 | 2021 | |
| Pfizer INC. | $34.42 | 2020 | |
| Mallinckrodt Hospital Products INC. | $30.21 | 2023 | Stratagraft |
| Sanara Medtech INC. | $23.35 | 2024 | Celleraterx |
| Merck Sharp & Dohme LLC | $18.31 | 2022 | |
| Esperion Therapeutics, INC. | $17.15 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.